Mouse over the small images above to change larger image and associated description. (Alternatively, read static PDF.)

Shown here is the crystal structure¹ of basiliximab binding to IL-2 overlaid with spheres representing atoms identified by wwavePDB analysis that form the contact surface between basiliximab and IL-2.

wwavePDB identifies the atoms forming the Ab/Ag contact surface and delivers detailed, easy to display information on the components and structure of the contact.

wwavePDB-identified contact atoms fill out volumes represented here by mesh surfaces:

•  purple surface encloses atoms in residues from the basiliximab H-chain that contact IL-2
•  cyan surface encloses atoms in residues from the basiliximab L-chain that contact IL-2
•  grey surface encloses atoms in residues from IL-2 that contact basiliximab

Basiliximab (Simulect; Novartis Pharmaceuticals, East Hanover, NJ) is an approved (1998) therapeutic antibody in the same class as daclizumab (Zenapax; Roche, Basel, Switzerland).

¹ Protein Data Bank ID: 3IU3.
   J. Du; H. Yang; D. Zhang; J. Wang; H. Guo; B. Peng; Y.Guo; J. Ding;
   “Structural basis for the blockage of the IL-2 signaling by therapeutic antibody basiliximab”
   J. Immunology (2010) 184(3): 1361-1368